Micromedex, a leader in clinical decision support for drug and toxicology information, released AI-powered search today, reflecting an ongoing commitment to innovation. Designed for healthcare ...

Objective Youth with childhood-onset SLE (cSLE) have increased risk of serious infection. It is unknown how much of this risk ...

A longitudinal neuroimaging study of youth with attention-deficit/hyperactivity disorder (ADHD) in Taiwan found that higher cumulative doses of methylphenidate were associated with increased gray ...

Since the hepatitis B vaccine was recommended for all babies at birth in 1991, new cases in the United States have declined significantly, especially among young people. The people at highest risk for ...

Background: Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are emerging as promising cell-free therapeutic agents due to their immunomodulatory and regenerative properties. However, ...

Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...

Compared to standard RTOG 1112 dosing, this model reduced liver toxicity risk while maintaining tumor control in most scenarios.

Can testosterone shots really boost energy and mood in women? Are peptides the secret to younger skin and stronger muscles? And what about those trendy IV vitamin drips popping up in spas and ...

The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...

The Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on November 7, 2023. The medicine is now available in a self-injecting pen, Leqembi Iqlik. Credit - ...

(Reuters) - Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of ...

Last week, HC Wainwright hosted Voyager Therapeutics, Inc.’s (NASDAQ:VYGR) management during HCW's Annual Global Investment Conference. The management emphasized recent preclinical murine data from a ...